ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
리소좀 효소 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 예측 기간 동안의 성장 전망은 희귀 질환 연구에 대한 투자 증가, 유전자 치료의 부상, 신생아 선별 검사 프로그램의 확대, 효소 대체 요법의 채택 증가, 바이오 의약품의 혁신, 희귀 의약품에 대한 지원적인 규제 프레임워크에 기인할 수 있습니다. 이 기간에 예상되는 주요 동향으로는 유전자 치료의 통합, 효소 대체 치료의 발전, 표적 약물 전달 시스템의 개발, 바이오마커 기반 진단 방법, 개인 맞춤형 치료 접근법, 혈액-뇌 장벽을 통과하는 기술의 개선, 치료 적용의 확대 등이 있습니다.
유전자 치료의 채택이 증가함에 따라 향후 몇 년 동안 리소좀 효소 시장이 성장할 것으로 예상됩니다. 유전자 치료는 환자의 세포 내 유전자를 수정하거나 교체하여 질병을 치료하거나 예방하는 의료적 접근법입니다. 전달 벡터의 발전과 장기적 효과의 입증으로 인해 채택이 증가하고 있으며, 유전적 질환에 대한 실용적이고 잠재적으로 치료 가능한 해결책으로 주목받고 있습니다. 유전자 치료는 유전자 치료가 효과를 발휘할 때까지 증상을 관리하고 환자의 상태를 안정화하기 위해 초기 또는 보완적인 효소 대체 요법이 필요로 하기 때문에 리소좀 효소 제품에 대한 수요를 유지합니다. 예를 들어, 2024년 4월 미국 유전자 및 세포 치료학회(American Society of Gene & Cell Therapy)는 2023년 제3상 유전자 치료 임상 시험 수가 10% 증가했다고 보고했습니다. 이는 2022년 이후 첫 분기별 성장입니다. 이에 따라 유전자 치료의 확산은 리소좀 효소 시장 확대를 지원할 것으로 예상됩니다.
리소좀 효소 시장 선도 기업들은 진단 능력 강화와 혁신적 치료제 개발 가속화를 위해 전략적 파트너십을 우선순위로 두고 있습니다. 전략적 파트너십은 조직 간 자원이나 전문성을 결합해 공동 목표 달성과 경쟁력 강화를 목표로 하는 협력 협약을 의미합니다. 예를 들어, 2024년 2월 스페인에 본사를 둔 바이오기술 기업은 아르헨티나 기반 바이오기술 기업 Biosidus와 협력해 활성 효소 성분 Agalsidase Beta를 생산하기 위한 파트너십을 체결했습니다. 이 파트너십은 리소좀 효소 결핍으로 인한 희귀 질환인 파브리병을 비롯한 희귀 질환 치료제 개발 및 생산에 중요한 진전을 의미합니다. 또한 희귀 질환 치료 분야에서 지역적 이정표가 될 것이며, 전 세계의 건강을 증진하고 접근성이 높은 바이오 의약품 혁신을 추진하기 위한 두 회사의 노력을 강조하는 계기가 될 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 리소좀 효소 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 리소좀 효소 시장 : 성장률 분석
세계의 리소좀 효소 시장 실적 : 규모와 성장(2019-2024년)
세계의 리소좀 효소 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 리소좀 효소 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 리소좀 효소 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
산성 α-글루코시다아제
산성 스핑고미에리나제
베타글루코세레브로시다아제
헥소사미니다제
세계의 리소좀 효소 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
고쉐병
뮤코다당증
폼페병
기타 적응증
세계의 리소좀 효소 시장 : 소스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
재조합 효소
천연 효소
합성 효소
세계의 리소좀 효소 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
효소 보충 요법
연구개발
진단
유전자 치료
세계의 리소좀 효소 시장 : 최종 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
진단실험실
연구기관
제약회사
세계의 리소좀 효소 시장 : 산성 α-글루코시다아제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
폼페병효소
글리코겐 저장병 II형 효소
세계의 리소좀 효소 시장 : 산성 스핑고미에리나아제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
니만-픽병 A형
니만-픽병 B형
세계의 리소좀 효소 시장 : β-글루코셀레브로시다아제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
고쉐병 I형
고쉐병 II형
고셰병 III형
세계의 리소좀 효소 시장 : 헥소사미니다제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
테이삭스병효소
샌드호프병 효소
제7장 지역별, 국가별 분석
세계의 리소좀 효소 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 리소좀 효소 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
리소좀 효소 시장 : 경쟁 구도
리소좀 효소 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
BioMarin Pharmaceutical Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Amicus Therapeutics Inc.
JCR Pharmaceuticals Co. Ltd.
Sangamo Therapeutics Inc.
Protalix BioTherapeutics Inc.
Orchard Therapeutics Plc
Alexion Pharmaceuticals Inc.
ISU Abxis Co. Ltd.
Chiesi Farmaceutici SpA
GC Pharma Co. Ltd.
Genzyme Corp.
Shire plc
Greenovation Biotech GmbH
Oxyrane
Avrobio Inc.
Ultragenyx Pharmaceutical Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
리소좀 효소 시장(2029년) : 새로운 기회를 제공하는 국가
리소좀 효소 시장(2029년) : 새로운 기회를 제공하는 부문
리소좀 효소 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Lysosomal enzymes are specialized hydrolytic enzymes located within lysosomes, which are membrane-bound organelles present in eukaryotic cells. These enzymes are essential for cellular digestion, as they break down a variety of biological macromolecules such as proteins, lipids, carbohydrates, and nucleic acids. A deficiency or dysfunction in these enzymes can result in serious genetic conditions known as lysosomal storage diseases, where undigested substances accumulate inside cells and impair their normal function.
The primary types of lysosomal enzymes include acid alpha-glucosidase, acid sphingomyelinase, beta-glucocerebrosidase, and hexosaminidase. Acid alpha-glucosidase functions to degrade glycogen into glucose within the lysosome. These enzymes are used to treat multiple disorders such as Gaucher disease, mucopolysaccharidosis, Pompe disease, and others. They are sourced from recombinant, natural, and synthetic origins and are applied in areas such as enzyme replacement therapy, research and development, diagnostics, and gene therapy. Their usage spans various environments including hospitals, diagnostic labs, research centers, and pharmaceutical companies.
The lysosomal enzyme market research report is one of a series of new reports from The Business Research Company that provides lysosomal enzyme market statistics, including the lysosomal enzyme industry global market size, regional shares, competitors with the lysosomal enzyme market share, detailed lysosomal enzyme market segments, market trends, and opportunities, and any further data you may need to thrive in the lysosomal enzyme industry. This lysosomal enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lysosomal enzymes market size has grown strongly in recent years. It will grow from $9.47 billion in 2024 to $10.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the increasing prevalence of lysosomal storage disorders, improved awareness and diagnosis rates, rising investments in rare disease research, favorable regulatory support, advancements in biotechnology, and enhanced access to orphan drugs.
The lysosomal enzymes market size is expected to see strong growth in the next few years. It will grow to $12.73 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The projected growth during the forecast period can be attributed to increased investments in rare disease research, the rise of gene therapy, the expansion of newborn screening programs, growing adoption of enzyme replacement therapies, emerging innovations in biopharmaceuticals, and supportive regulatory frameworks for orphan drugs. Key trends expected in this period include the integration of gene therapy, advancements in enzyme replacement treatments, development of targeted drug delivery systems, biomarker-based diagnostic methods, personalized therapeutic approaches, improved techniques for crossing the blood-brain barrier, and broadened therapeutic applications.
The rising adoption of gene therapy is expected to drive the growth of the lysosomal enzymes market in the coming years. Gene therapy is a medical approach that involves modifying or replacing genes within a patient's cells to treat or prevent disease. Its adoption is growing due to advancements in delivery vectors and proven long-term effectiveness, making it a viable and potentially curative solution for genetic disorders. Gene therapy often necessitates initial or complementary enzyme replacement therapy to manage symptoms and stabilize patients while the gene therapy becomes effective, thereby maintaining the demand for lysosomal enzyme products. For example, in April 2024, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported that the number of phase III gene therapy clinical trials increased by 10% in 2023, representing the first quarterly growth since 2022. As a result, the growing use of gene therapy is expected to support the expansion of the lysosomal enzymes market.
Leading companies in the lysosomal enzymes market are prioritizing strategic partnerships to enhance diagnostic capabilities and accelerate the development of innovative therapies. Strategic partnerships involve collaborative agreements between organizations that pool resources or expertise to achieve shared objectives and strengthen their competitive positioning. For example, in February 2024, a biotechnology company based in Spain entered into a partnership with Biosidus, an Argentina-based biotechnology firm, to produce the active enzyme ingredient Agalsidase Beta. This partnership represents a significant step forward in the development and production of treatments for rare diseases, particularly Fabry disease, which is caused by a lysosomal enzyme deficiency. It also marks a regional milestone in rare disease care and underscores the companies' dedication to advancing global health and promoting accessible biopharmaceutical innovation.
In March 2024, CENTOGENE, a biotechnology research company based in Germany, formed a partnership with Takeda Pharmaceutical Company Limited. This collaboration aims to enhance global access to fast and accurate diagnostics for rare lysosomal diseases, thereby supporting earlier detection and improved treatment outcomes, particularly in underserved populations. Takeda Pharmaceutical Company Limited is a Japan-based supplier of lysosomal enzymes.
Major players in the lysosomal enzyme market are Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Protalix BioTherapeutics Inc., Orchard Therapeutics Plc, Alexion Pharmaceuticals Inc., ISU Abxis Co. Ltd., Chiesi Farmaceutici S.p.A., GC Pharma Co. Ltd., Genzyme Corp., Shire plc, Greenovation Biotech GmbH, Oxyrane, Avrobio Inc., Ultragenyx Pharmaceutical Inc.
North America was the largest region in the lysosomal enzymes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lysosomal enzymes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the lysosomal enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The lysosomal enzymes market consists of sales of small molecule drugs, diagnostic kits, nutritional supplements, infusion kits, and accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lysosomal Enzyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on lysosomal enzyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for lysosomal enzyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lysosomal enzyme market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Acid Alpha-Glucosidase; Acid Sphingomyelinase; Beta-Glucocerebrosidase; Hexosaminidase
2) By Indication: Gaucher Disease; Mucopolysaccharidosis; Pompe Disease; Other Indications
3) By Source: Recombinant Enzymes; Natural Enzymes; Synthetic Enzymes
4) By Application: Enzyme Replacement Therapy; Research And Development; Diagnostics; Gene Therapy
5) By End-Use: Hospitals; Diagnostic Laboratories; Research Institutions; Pharmaceutical Companies
Subsegments:
1) By Acid Alpha-Glucosidase: Pompe Disease Enzymes; Glycogen Storage Disease Type II Enzymes
2) By Acid Sphingomyelinase: Niemann-Pick Disease Type A; Niemann-Pick Disease Type B
3) By Beta-Glucocerebrosidase: Gaucher Disease Type I; Gaucher Disease Type II; Gaucher Disease Type III
4) By Hexosaminidase: Tay-Sachs Disease Enzymes; Sandhoff Disease Enzymes
Companies Mentioned: Pfizer Inc.; Sanofi SA; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; BioMarin Pharmaceutical Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Lysosomal Enzyme Market Characteristics
3. Lysosomal Enzyme Market Trends And Strategies
4. Lysosomal Enzyme Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Lysosomal Enzyme Growth Analysis And Strategic Analysis Framework
5.1. Global Lysosomal Enzyme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lysosomal Enzyme Market Growth Rate Analysis
5.4. Global Lysosomal Enzyme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lysosomal Enzyme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lysosomal Enzyme Total Addressable Market (TAM)
6. Lysosomal Enzyme Market Segmentation
6.1. Global Lysosomal Enzyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acid Alpha-Glucosidase
Acid Sphingomyelinase
Beta-Glucocerebrosidase
Hexosaminidase
6.2. Global Lysosomal Enzyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gaucher Disease
Mucopolysaccharidosis
Pompe Disease
Other Indications
6.3. Global Lysosomal Enzyme Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Enzymes
Natural Enzymes
Synthetic Enzymes
6.4. Global Lysosomal Enzyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy
Research And Development
Diagnostics
Gene Therapy
6.5. Global Lysosomal Enzyme Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies
6.6. Global Lysosomal Enzyme Market, Sub-Segmentation Of Acid Alpha-Glucosidase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pompe Disease Enzymes
Glycogen Storage Disease Type II Enzymes
6.7. Global Lysosomal Enzyme Market, Sub-Segmentation Of Acid Sphingomyelinase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Niemann-Pick Disease Type A
Niemann-Pick Disease Type B
6.8. Global Lysosomal Enzyme Market, Sub-Segmentation Of Beta-Glucocerebrosidase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gaucher Disease Type I
Gaucher Disease Type II
Gaucher Disease Type III
6.9. Global Lysosomal Enzyme Market, Sub-Segmentation Of Hexosaminidase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tay-Sachs Disease Enzymes
Sandhoff Disease Enzymes
7. Lysosomal Enzyme Market Regional And Country Analysis
7.1. Global Lysosomal Enzyme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lysosomal Enzyme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
